Result of Annual General Meeting
Arix Bioscience PLC (ARIX)
Result of Annual General Meeting
23-May-2023 / 16:30 GMT/BST
Arix Bioscience plc
Result of Annual General Meeting
LONDON, 23 May 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.
Full details of the poll results are set out below and will also be available on the Company's .
No
RESOLUTION
VOTES FOR
%
VOTES AGAINST
%
TOTAL VOTES
% of ISC VOTED
VOTES WITHHELD
1
To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2022
68,931,411
100.00%
3,441
0.00%
68,934,852
53.28%
8,440
2
To approve the Directors' Remuneration Report
61,073,950
89.25%
7,358,207
10.75%
68,432,157
52.89%
511,135
3
To re-elect Peregrine Moncreiffe as a Director
68,099,019
98.79%
834,821
1.21%
68,933,840
53.28%
9,452
4
To re-elect Maureen O'Connell as a Director
68,894,053
99.94%
42,077
0.06%
68,936,130
53.28%
7,162
5
To re-elect Isaac Kohlberg as a Director
68,900,656
99.98%
17,184
0.02%
68,917,840
53.26%
25,452
6
To re-elect Robert Lyne as a Director
68,902,689
99.95%
31,595
0.05%
68,934,284
53.28%
9,008
7
To elect Dr. Debra Barker as a Director
68,907,528
99.95%
32,248
0.05%
68,939,776
53.28%
3,516
8
To elect Andrew Smith as a Director
68,921,195
99.98%
13,089
0.02%
68,934,284
53.28%
9,008
9
To appoint BDO LLP as auditors of the Company
68,929,881
99.99%
7,445
0.01%
68,937,326
53.28%
5,966
10
To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration
68,934,245
100.00%
2,013
0.00%
68,936,258
53.28%
7,034
11
To authorise the Directors to allot shares
65,989,256
95.72%
2,950,520
4.28%
68,939,776
53.28%
3,516
12
Authority to disapply statutory pre‐ emption rights
62,199,252
90.23%
6,734.680
9.77%
68,933,932
53.28%
9,360
13
Additional authority to disapply statutory pre‐ emption rights
62,202,105
90.23%
6,731,827
9.77%
68,933,932
53.28%
9,360
14
To authorise the Company to purchase its own shares
68,921,128
99.98%
17,177
0.02%
68,938,305
53.28%
4,987
15
Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice
68,145,351
98.85%
792,954
1.15%
68,938,305
53.28%
4,987
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at .
The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 25 April 2023, which is available on Arix investor relations .
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
ISIN: GB00BD045071 Category Code: RAG TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 245804 EQS News ID: 1639935
End of Announcement EQS News Service